---
document_datetime: 2025-12-09 23:29:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kaletra.html
document_name: kaletra.html
version: success
processing_time: 0.1476265
conversion_datetime: 2025-12-28 17:40:21.959717
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kaletra

[RSS](/en/individual-human-medicine.xml/66685)

##### Authorised

This medicine is authorised for use in the European Union

lopinavir / ritonavir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kaletra](#news-on)
- [More information on Kaletra](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Kaletra. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Kaletra.

For practical information about using Kaletra, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Kaletra and what is it used for?

Kaletra is an HIV medicine used in combination with other medicines to treat adults and children from over 14 days of age who are infected with HIV?1. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

Kaletra contains two active substances, lopinavir and ritonavir.

## How is Kaletra used?

Kaletra is available as tablets, capsules and oral liquid. The capsules and liquid must be taken with food, but the tablets can be taken with or without food.

The medicine is taken once or twice daily in adults, and the dose depends on the type of virus the patient is infected with. In children, the dose depends on body weight and height.

Kaletra can only be obtained with a prescription and should be prescribed by a doctor with experience treating HIV infection. For further information, see the package leaflet.

## How does Kaletra work?

Both active substances in Kaletra are protease inhibitors: they block an enzyme called protease that is involved in the reproduction of HIV. When the enzyme is blocked, the virus does not reproduce normally slowing down its multiplication in the body. In Kaletra, lopinavir provides the activity against the virus while ritonavir mainly works as a 'booster' to slow down the rate at which lopinavir is broken down by the liver. Kaletra does not cure HIV infection or AIDS, but it may hold off damage to the immune system, and the development of infections and diseases associated with AIDS.

## What benefits of Kaletra have been shown in studies?

Studies have shown that Kaletra is effective at reducing viral load (the amount of virus found in the blood) to very low levels (below 400 copies/ml).

In one study of adults who had not been treated for HIV before, 79% of the patients taking Kaletra (259 out of 326) had very low levels of the virus after 24 weeks, compared with 71% of the patients taking nelfinavir (233 out of 327).

A second adult study in patients who had previously taken a protease inhibitor, 73% of the patients taking Kaletra (43 out of 59) had very low levels of the virus after 16 weeks, compared with 54% of the patients taking the comparator medicines (32 out of 59).

Studies in children from 14 days of age showed between 71% and 85% of patients having very low levels of the virus after 48 weeks of treatment with Kaletra.

## What are the risks associated with Kaletra?

The most common side effects with Kaletra in adults (seen in more than 1 patient in 10) are upper respiratory tract infection (colds), nausea (feeling sick) and diarrhoea. Side effects are similar in children. For the full list of all side effects reported with Kaletra, see the package leaflet.

Kaletra must not be used by patients with severe liver disease or by patients who are taking St John's wort (a herbal preparation used to treat depression) or medicines that are broken down in the same way as Kaletra and are harmful at high levels in the blood. For the full list of restrictions, see the package leaflet.

## Why is Kaletra approved?

Kaletra is effective at reducing HIV viral loads to below 400 copies/ml in the majority of adults and children from 14 days of age. The medicine is also well tolerated and its side effects are manageable. The European Medicines Agency (EMA) therefore concluded that the benefits of Kaletra outweigh its risks and recommended that it be given marketing authorisation in the EU.

## What measures are being taken to ensure the safe and effective use of Kaletra?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kaletra have been included in the summary of product characteristics and the package leaflet.

## Other information about Kaletra

The European Commission granted a marketing authorisation valid throughout the European Union for Kaletra on 20 March 2001.

For more information about treatment with Kaletra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Kaletra : EPAR - Summary for the public

English (EN) (79.59 KB - PDF)

**First published:** 23/09/2009

**Last updated:** 30/10/2017

[View](/en/documents/overview/kaletra-epar-summary-public_en.pdf)

[Other languages (24)](#file-language-dropdown-558)

български (BG) (105.21 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/bg/documents/overview/kaletra-epar-summary-public_bg.pdf)

español (ES) (79.29 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/es/documents/overview/kaletra-epar-summary-public_es.pdf)

čeština (CS) (104.29 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/cs/documents/overview/kaletra-epar-summary-public_cs.pdf)

dansk (DA) (78.28 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/da/documents/overview/kaletra-epar-summary-public_da.pdf)

Deutsch (DE) (80.1 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/de/documents/overview/kaletra-epar-summary-public_de.pdf)

eesti keel (ET) (77.12 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/et/documents/overview/kaletra-epar-summary-public_et.pdf)

ελληνικά (EL) (108.25 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/el/documents/overview/kaletra-epar-summary-public_el.pdf)

français (FR) (79.64 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/fr/documents/overview/kaletra-epar-summary-public_fr.pdf)

hrvatski (HR) (99.12 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/hr/documents/overview/kaletra-epar-summary-public_hr.pdf)

íslenska (IS) (645.85 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/is/documents/overview/kaletra-epar-summary-public_is.pdf)

italiano (IT) (78.69 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/it/documents/overview/kaletra-epar-summary-public_it.pdf)

latviešu valoda (LV) (101.25 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/lv/documents/overview/kaletra-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (102.48 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/lt/documents/overview/kaletra-epar-summary-public_lt.pdf)

magyar (HU) (100.22 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/hu/documents/overview/kaletra-epar-summary-public_hu.pdf)

Malti (MT) (183.98 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/mt/documents/overview/kaletra-epar-summary-public_mt.pdf)

Nederlands (NL) (78.76 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/nl/documents/overview/kaletra-epar-summary-public_nl.pdf)

norsk (NO) (627.86 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/no/documents/overview/kaletra-epar-summary-public_no.pdf)

polski (PL) (105.13 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/pl/documents/overview/kaletra-epar-summary-public_pl.pdf)

português (PT) (79.11 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/pt/documents/overview/kaletra-epar-summary-public_pt.pdf)

română (RO) (101.54 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/ro/documents/overview/kaletra-epar-summary-public_ro.pdf)

slovenčina (SK) (104.04 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/sk/documents/overview/kaletra-epar-summary-public_sk.pdf)

slovenščina (SL) (97.29 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/sl/documents/overview/kaletra-epar-summary-public_sl.pdf)

Suomi (FI) (78.25 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/fi/documents/overview/kaletra-epar-summary-public_fi.pdf)

svenska (SV) (78.74 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

30/10/2017

[View](/sv/documents/overview/kaletra-epar-summary-public_sv.pdf)

Kaletra : EPAR - Risk management plan

English (EN) (2.42 MB - PDF)

**First published:** 02/04/2020

**Last updated:** 20/01/2025

[View](/en/documents/rmp/kaletra-epar-risk-management-plan_en.pdf)

## Product information

Kaletra : EPAR - Product Information

English (EN) (907.89 KB - PDF)

**First published:** 23/09/2009

**Last updated:** 02/12/2025

[View](/en/documents/product-information/kaletra-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-232)

български (BG) (1.09 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/bg/documents/product-information/kaletra-epar-product-information_bg.pdf)

español (ES) (906.21 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/es/documents/product-information/kaletra-epar-product-information_es.pdf)

čeština (CS) (1.1 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/cs/documents/product-information/kaletra-epar-product-information_cs.pdf)

dansk (DA) (871.21 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/da/documents/product-information/kaletra-epar-product-information_da.pdf)

Deutsch (DE) (1.02 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/de/documents/product-information/kaletra-epar-product-information_de.pdf)

eesti keel (ET) (887.54 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/et/documents/product-information/kaletra-epar-product-information_et.pdf)

ελληνικά (EL) (1.15 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/el/documents/product-information/kaletra-epar-product-information_el.pdf)

français (FR) (1.02 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/fr/documents/product-information/kaletra-epar-product-information_fr.pdf)

hrvatski (HR) (1.04 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/hr/documents/product-information/kaletra-epar-product-information_hr.pdf)

íslenska (IS) (912.91 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/is/documents/product-information/kaletra-epar-product-information_is.pdf)

italiano (IT) (994.15 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/it/documents/product-information/kaletra-epar-product-information_it.pdf)

latviešu valoda (LV) (1.04 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/lv/documents/product-information/kaletra-epar-product-information_lv.pdf)

lietuvių kalba (LT) (977.5 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/lt/documents/product-information/kaletra-epar-product-information_lt.pdf)

magyar (HU) (1.09 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/hu/documents/product-information/kaletra-epar-product-information_hu.pdf)

Malti (MT) (1.15 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/mt/documents/product-information/kaletra-epar-product-information_mt.pdf)

Nederlands (NL) (927.91 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/nl/documents/product-information/kaletra-epar-product-information_nl.pdf)

norsk (NO) (888.61 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/no/documents/product-information/kaletra-epar-product-information_no.pdf)

polski (PL) (1.09 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/pl/documents/product-information/kaletra-epar-product-information_pl.pdf)

português (PT) (893.45 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/pt/documents/product-information/kaletra-epar-product-information_pt.pdf)

română (RO) (1.01 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/ro/documents/product-information/kaletra-epar-product-information_ro.pdf)

slovenčina (SK) (1.11 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/sk/documents/product-information/kaletra-epar-product-information_sk.pdf)

slovenščina (SL) (1.01 MB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/sl/documents/product-information/kaletra-epar-product-information_sl.pdf)

Suomi (FI) (911.22 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/fi/documents/product-information/kaletra-epar-product-information_fi.pdf)

svenska (SV) (883.24 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

02/12/2025

[View](/sv/documents/product-information/kaletra-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000278292 30/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kaletra : EPAR - All Authorised presentations

English (EN) (29.26 KB - PDF)

**First published:** 23/09/2009

**Last updated:** 10/04/2025

[View](/en/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-287)

български (BG) (39.04 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/bg/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_bg.pdf)

español (ES) (30.73 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/es/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_es.pdf)

čeština (CS) (40.23 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/cs/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (30.83 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/da/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.26 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/de/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (29.85 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/et/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (37.2 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/el/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_el.pdf)

français (FR) (35.4 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/fr/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (38.72 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/hr/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (30.49 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/is/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_is.pdf)

italiano (IT) (30.34 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/it/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (41.43 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/lv/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (40.67 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/lt/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (38.91 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/hu/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.59 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/mt/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (30.66 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/nl/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (30.62 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/no/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_no.pdf)

polski (PL) (41.53 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/pl/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_pl.pdf)

português (PT) (31.99 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/pt/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_pt.pdf)

română (RO) (39.15 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/ro/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (40.17 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/sk/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (35.89 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/sl/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (28.62 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/fi/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (30.57 KB - PDF)

**First published:**

23/09/2009

**Last updated:**

10/04/2025

[View](/sv/documents/all-authorised-presentations/kaletra-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kaletra Active substance

- lopinavir
- ritonavir

International non-proprietary name (INN) or common name

- lopinavir
- ritonavir

Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AR10

### Pharmacotherapeutic group

- Antivirals for systemic use
- Protease inhibitors

### Therapeutic indication

Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.

The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

## Authorisation details

EMA product number EMEA/H/C/000368 Marketing authorisation holder

AbbVie Deutschland GmbH &amp; Co. KG

Knollstrasse 67061 Ludwigshafen Germany

Opinion adopted 14/12/2000 Marketing authorisation issued 19/03/2001 Revision 65

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kaletra : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (152.18 KB - PDF)

**First published:** 10/04/2025

**Last updated:** 02/12/2025

[View](/en/documents/procedural-steps-after/kaletra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Kaletra : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (430.74 KB - PDF)

**First published:** 23/09/2009

**Last updated:** 10/04/2025

[View](/en/documents/procedural-steps-after/kaletra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Kaletra-H-C-368-II-0161-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/443456/2017

English (EN) (1.34 MB - PDF)

**First published:** 30/10/2017

**Last updated:** 30/10/2017

[View](/en/documents/variation-report/kaletra-h-c-368-ii-0161-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Kaletra

Adopted

Reference Number: EMA/CHMP/377673/2017

English (EN) (66.6 KB - PDF)

**First published:** 23/06/2017

**Last updated:** 23/06/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kaletra_en.pdf)

Kaletra-H-C-368-P45-0099 : EPAR - Assessment Report

Adopted

Reference Number: EMA/632830/2012

English (EN) (203.59 KB - PDF)

**First published:** 20/08/2013

**Last updated:** 20/08/2013

[View](/en/documents/variation-report/kaletra-h-c-368-p45-0099-epar-assessment-report_en.pdf)

Kaletra-H-C-368-X-0027 : EPAR - Scientific Discussion - Extension

Adopted

English (EN) (167.93 KB - PDF)

**First published:** 23/09/2009

**Last updated:** 23/09/2009

[View](/en/documents/scientific-discussion-variation/kaletra-h-c-368-x-0027-epar-scientific-discussion-extension_en.pdf)

Kaletra : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (107.08 KB - PDF)

**First published:** 09/08/2006

**Last updated:** 09/08/2006

[View](/en/documents/steps-after-cutoff/kaletra-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Kaletra : EPAR - Procedural steps taken before authorisation

English (EN) (92.83 KB - PDF)

**First published:** 09/08/2006

**Last updated:** 09/08/2006

[View](/en/documents/procedural-steps/kaletra-epar-procedural-steps-taken-authorisation_en.pdf)

Kaletra : EPAR - Scientific Discussion

English (EN) (320.24 KB - PDF)

**First published:** 09/08/2006

**Last updated:** 09/08/2006

[View](/en/documents/scientific-discussion/kaletra-epar-scientific-discussion_en.pdf)

#### News on Kaletra

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2017) 23/06/2017

[Updated advice on body fat changes and lactic acidosis with HIV medicines](/en/news/updated-advice-body-fat-changes-lactic-acidosis-hiv-medicines) 23/10/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-october-2015) 23/10/2015

#### More information on Kaletra

- [EMEA-001005-PIP01-10-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001005-pip01-10-m01)
- [Kaletra - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/kaletra)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/12/2025

## Share this page

[Back to top](#main-content)